Miltenyi Biotec will supply lentiviral vector for TECELRA® (afamitresgene autoleucel), the first-ever TCR T-cell therapy for solid tumors approved by FDA on August 1, 2024.
The commercial manufacturing of the lentiviral vector used in production of TECELRA is performed by Miltenyi Bioindustry, the global division of Miltenyi Biotec dedicated to contract development and manufacturing organization (CDMO) services for the manufacturing of viral vectors and gene-engineered cell therapy products.